Calcineurin inhibitors in chronic urticaria

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 4, 2012, Pages 412-420

  Trojan, Timothy D ^a   Khan, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

calcineurin inhibitors; chronic idiopathic urticaria; chronic urticaria; cyclosporine; tacrolimus

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CREATININE; CYCLOSPORIN; DAPSONE; FC RECEPTOR; FK 506 BINDING PROTEIN; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; ARTHRITIS; BACKACHE; BASOPHIL; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLU LIKE SYNDROME; GINGIVA HYPERPLASIA; HEALTH CARE COST; HIRSUTISM; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; IDIOPATHIC DISEASE; INFECTION; LONG TERM CARE; LOW DRUG DOSE; MAST CELL; MEDICAL RECORD REVIEW; MYALGIA; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; REVIEW; SIDE EFFECT; SKIN TINGLING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

CALCINEURIN; CHRONIC DISEASE; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TACROLIMUS; TIME FACTORS; URTICARIA;

EID: 84864289539     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32835571f6     Document Type: Review

References (50)

1. Gaig P, Olona M, Munoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14:214-220. (Pubitemid 39390277)
2. Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010; 35:869-873.
3. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66:317-330.
4. Tarbox JA, Gutta RC, Radojicic C, et al. Utility of routine laboratory testing in management of chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2011; 107:239-243.
5. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125:676-682.
6. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635-638. (Pubitemid 28212248)
7. Zuberbier T. Pharmacological rationale for the treatment of chronic urticaria with second-generation nonsedating antihistamines at higher-than-standard doses. J Eur Acad Dermatol Venereol 2012; 26:9-18.
8. Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J Clin Dermatol 2011; 12:361-376.
9. Kessel A, Toubi E. Low-dose cyclosporine is a good option for severe chronic urticaria. J Allergy Clin Immunol 2009; 123:970.
10. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-1443.
11. Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34:1401-1407. (Pubitemid 39233695)
12. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113:134-140. (Pubitemid 38096173)
13. Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694-700. (Pubitemid 34327199)
14. Hide M, Francis DM, Grattan C, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-1604. (Pubitemid 23151920)
15. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008; 20:709-716.
16. Sun R-S, Sui J-F, Chen X-H, et al. Detection of CD4+CD25+FOXP3+ regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria. Australas J Dermatol 2011; 52:e15-e18.
17. Sperr WR, Agis H, Czerwenka K, et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol 1996; 98:389-399. (Pubitemid 26326133)
18. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Derma 1992; 99:723-728. (Pubitemid 23002033)
19. Casolaro V, Spadaro G, Patella V, et al. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993; 151:5563-5573. (Pubitemid 23332366)
20. Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990; 144:3891-3897. (Pubitemid 20171202)
21. Marsland AM, Soundararajan S, Joseph K, et al. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy 2005; 35:554-559. (Pubitemid 40769276)
22. Grattan CEH, ODonnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic urticaria. Br J Dermatol 2000; 143:365-372. (Pubitemid 30650407)
23. Brandt C, Pavlovic V, Radbruch A, et al. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009; 64:1588-1596.
24. Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55:705-709. (Pubitemid 44444850)
25. Baskan EB, Tunali S, Turker T, et al. Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria. J Dermatolog Treat 2004; 15:164-168. (Pubitemid 39214577)
26. Loria MP, Dambra PP, DOronzio L, et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 2001; 23:205-213. (Pubitemid 32532047)
27. Serhat Inaloz H, Ozturk S, Akcali C, et al. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol 2008; 35:276-282. (Pubitemid 351678094)
28. Toubi E, Blant A, Kessel A, et al. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52:312-316. (Pubitemid 27166233)
29. Boubouka CD, Charissi C, Kouimintzis D, et al. Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up. Acta Derm Venereol 2011; 91:50-54.
30. Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24:285-290. (Pubitemid 37152336)
31. Ohtsuka T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int J Dermatol 2010; 49:579-584.
32. Ilter N, Gurer MA, Akkoca MA. Short-term oral cyclosporine for chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 1999; 12: 67-69. (Pubitemid 29132994)
33. Fradin MS, Ellis CN, Goldfarb MT, et al. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991; 25 (Pt 1):1065-1067.
34. Hollander SM, Joo SS, Wedner HJ. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol V 107 2011; 523-528.
35. Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010; 65:1478-1482.
36. Di Leo E, Nettis E, Aloia AM, et al. Cyclosporin-A efficacy in chronic idiopathic urticaria. Int J Immunopathol Pharmacol 2011; 24:195-200.
37. Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009; 26:409-413.
38. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Investig Dermatol 2003; 120:211-216. (Pubitemid 36513069)
39. Chen Y-J,WuC-Y, Chen T-J, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011; 65:84-91
40. Vakeva L, Reitamo S, Pukkala E, et al. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol 2008; 88:117-120. (Pubitemid 351507180)
41. van den Borne BEEM, Landewe RBM, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1930-1937. (Pubitemid 28506681)
42. Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience: a comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat 2011. [Epub ahead of print]. DOI: 10.3109/09546634. 2011.590792
43. Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130:366-375. (Pubitemid 24204648)
44. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporine (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999; 141:283-291. (Pubitemid 29397997)
45. Messana JM, Johnson KJ, Mihatsch MJ. Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report. Clin Nephrol 1995; 43:150-153.
46. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in nonplaque psoriasis. J Eur Acad Dermatol Venereol 2011; 25:19-27.
47. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther 2007; 20:239-250. (Pubitemid 350029313)
48. Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005; 52:145-148. (Pubitemid 40038952)
49. Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62:838-853.
50. DeLong LK, Culler SD, Saini SS, et al. Annual direct and indirect healthcare costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008; 144:35-39. (Pubitemid 351159387)